ly-233053 and Ischemia

ly-233053 has been researched along with Ischemia* in 2 studies

Other Studies

2 other study(ies) available for ly-233053 and Ischemia

ArticleYear
Delayed therapy of experimental ischemia with competitive N-methyl-D-aspartate antagonists in rabbits.
    Stroke, 1993, Volume: 24, Issue:7

    N-methyl-D-aspartate antagonists are effective in limiting ischemic damage to the brain and spinal cord if treatment is begun at time of ischemic injury. More clinically relevant delayed therapy has not been adequately investigated. We report the temporal profile of efficacy for two competitive N-methyl-D-aspartate antagonists in therapy of central nervous system ischemia.. CGS-19755 (30 mg/kg) or LY233053 (100 mg/kg) was administered 5, 30, or 60 minutes after reversible spinal cord ischemia in rabbits, induced by temporary occlusion of the infrarenal aorta. Duration of occlusion for individual animals was varied to provide a range of ischemia for each experimental group. The P50 represents the duration (in minutes) associated with a 50% probability of resultant permanent paraplegia. Neuroprotection is demonstrated if a drug prolongs the P50.. CGS-19755 significantly prolonged the P50 (t test, P = .003) when given 5 minutes after ischemia, but not if delayed by 30 or 60 minutes (P50: control, 24.1; 5 minutes, 31.4; 30 minutes, 30.1; 60 minutes, 26.6). LY233053 was efficacious at 5 (P = .0008) and 30 (P = .002) minutes, but not at 60 minutes (P50: control, 26.8; 5 minutes, 39.4; 30 minutes, 36.0; 60 minutes, 25.6).. These competitive N-methyl-D-aspartate antagonists are effective in limiting ischemic damage, but protection is lost if therapy is not initiated within 60 minutes of injury.

    Topics: Animals; Ischemia; N-Methylaspartate; Paraplegia; Pipecolic Acids; Rabbits; Receptors, N-Methyl-D-Aspartate; Spinal Cord; Tetrazoles; Time Factors

1993
Efficacy of LY233053, a competitive glutamate antagonist, in experimental central nervous system ischemia.
    Journal of neurosurgery, 1992, Volume: 76, Issue:1

    Antagonists of excitatory amino acids appear to serve a neuroprotective role during ischemic conditions in a variety of in vivo and in vitro models. The usefulness of such agents in the clinical setting, however, may be limited by poor central nervous system (CNS) entry and intolerable side effects. The authors report high efficacy in reducing neurological damage and relatively limited side effects of LY233053, a novel competitive glutamate antagonist, in two models of experimental CNS ischemia in the rabbit.

    Topics: Animals; Brain Ischemia; Dose-Response Relationship, Drug; Ischemia; N-Methylaspartate; Pipecolic Acids; Rabbits; Spinal Cord; Tetrazoles

1992